(Q35094669)

6 August 2017

1 reference

title

Novel therapies for renal cell carcinoma--an update (English)

1 reference

6 August 2017

Mayer Fishman

1

1 reference

6 August 2017

Scott Antonia

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

4

1 reference

6 August 2017

page(s)

593-609

1 reference

Novel therapies for renal cell carcinoma

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Phase II trial of thalidomide in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

The treatment of advanced renal cell cancer with high-dose oral thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Transcriptional control by the TGF-beta/Smad signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

TGF-beta1 regulation of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Two HIFs may be better than one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Interleukin-2 and histamine dihydrochloride in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Active immunization against cancer with dendritic cells: the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Cytokine-secreting tumor cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.4.593

10.1517/13543784.12.4.593

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference